Ranibizumab biosimilar - BIOCND

Drug Profile

Ranibizumab biosimilar - BIOCND

Alternative Names: BCD 300; QL 1205

Latest Information Update: 24 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BIOCND
  • Developer BIOCND; Qilu Pharmaceutical
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Macular degeneration; Wet age-related macular degeneration

Most Recent Events

  • 01 Oct 2017 Phase-I clinical trials in Wet age-related macular degeneration in China (IV) (NCT03312283)
  • 26 Jul 2017 Phase-I clinical trials in Macular degeneration in South Korea (unspecified route) (BIOCND pipeline, July 2017)
  • 26 Jul 2017 BIOCND announces intention to submit marketing authorisation for Macular degenration in 2020 (BIOCND pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top